SLS vs. VTVT, ANEB, RVPH, LPTX, IFRX, AFMD, RLYB, YS, TPST, and LFVN
Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include vTv Therapeutics (VTVT), Anebulo Pharmaceuticals (ANEB), Reviva Pharmaceuticals (RVPH), Leap Therapeutics (LPTX), InflaRx (IFRX), Affimed (AFMD), Rallybio (RLYB), YS Biopharma (YS), Tempest Therapeutics (TPST), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry.
SELLAS Life Sciences Group (NASDAQ:SLS) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.
In the previous week, SELLAS Life Sciences Group and SELLAS Life Sciences Group both had 6 articles in the media. vTv Therapeutics' average media sentiment score of 0.65 beat SELLAS Life Sciences Group's score of 0.25 indicating that vTv Therapeutics is being referred to more favorably in the news media.
SELLAS Life Sciences Group presently has a consensus price target of $3.00, indicating a potential upside of 104.08%. Given SELLAS Life Sciences Group's higher possible upside, analysts clearly believe SELLAS Life Sciences Group is more favorable than vTv Therapeutics.
vTv Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.
vTv Therapeutics received 341 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. However, 58.82% of users gave SELLAS Life Sciences Group an outperform vote while only 57.73% of users gave vTv Therapeutics an outperform vote.
17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 1.6% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 1.7% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
SELLAS Life Sciences Group has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
vTv Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. vTv Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
Summary
vTv Therapeutics beats SELLAS Life Sciences Group on 8 of the 15 factors compared between the two stocks.
Get SELLAS Life Sciences Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SELLAS Life Sciences Group Competitors List
Related Companies and Tools
